Table 3 Univariate and multivariate Cox regression analyses for the Child Pugh class A patients only (N = 195): Non-Viral (N = 47), Viral (N = 148).

From: Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors

 

Univariate OS*

Univariate PFS

Multivariate PFS

HR; 95% CI

P value

HR; 95% CI

P value

HR; 95% CI

P value

Age

≥ median vs. < median

0.79;

0.54–1.1

0.21

0.91;

0.66–1.2

0.55

  

Gender

Male vs. Female

0.83;

0.49–1.4

0.50

1.0;

0.67–1.6

0.93

  

Cirrhosis

Yes vs. No

0.95;

0.57–1.6

0.84

0.81;

0.53–1.2

0.34

  

Tumor Size

≥ median vs. < median

1.2;

0.79–1.7

0.45

1.0;

0.72–1.4

0.99

  

Extrahepatic

Yes vs. No

1.0;

0.69–1.5

0.96

1.0;

0.73–1.4

0.94

  

PVTT

Yes vs. No

1.3;

0.86–1.8

0.25

0.93;

0.67–1.3

0.65

  

PVTT Class

vp 3–4 vs. vp 0–2

1.1;

0.75–1.7

0.56

0.98;

0.70–1.4

0.91

  

MVI

Yes vs. No

1.3;

0.91–1.9

0.15

1.0;

0.73–1.4

0.98

  

ECOG PS

 ≥ 1 vs. 0

1.2;

0.75–1.9

0.35

1.5;

1.0–2.2

0.034**

1.5;

1.0–2.2

0.038**

BMI

 ≥ 25 vs. < 25

0.96;

0.65–1.4

0.85

1.1;

0.82–1.6

0.45

  

BCLC Stage

C vs. A/B

1.2;

0.78–1.9

0.41

0.94;

0.66-1.4

0.75

  

AFP

 < 400 vs. ≥ 400

1.2;

0.8–1.7

0.41

0.96;

0.69–1.3

0.79

  

Etiology

Non-Viral vs. Viral

1.8;

1.2–2.7

0.005**

2.0;

1.4–2.8

<0.001**

1.9;

1.3–2.7

<0.001**

ICI Regimen

Combo vs. Mono

0.7;

0.47–1.2

0.18

0.65;

0.46–0.94

0.020**

0.73;

0.51–1.1

0.096

Concurrent LRT

Yes vs. No

1.3;

0.86–1.8

0.24

1.1;

0.81–1.5

0.49

  
  1. *None of the variables was independently associated with overall survival in the multivariate analysis
  2. **Statistically significant (P value < 0.05)
  3. OS overall survival, PFS progression-free survival, HR hazard ratio, CI confidence interval, PVTT portal vein tumor thrombosis, MVI macrovascular invasion, ECOG PS Eastern Cooperative Oncology Group performance status, BMI body mass index, BCLC Barcelona Clinic Liver Cancer, AFP alpha fetoprotein, ICI immune checkpoint inhibitor, LRT locoregional therapy.